FPI-1966
- Generic Name
- FPI-1966
A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
Phase 1
Terminated
- Conditions
- Bladder CarcinomaHead and Neck Squamous Cell CarcinomaSusceptible FGFR3 Genetic AlterationsBreast CancerFGFR3 ReceptorFGFR3 Protein OverexpressionColorectal CancerLiver CancerAdvanced Solid TumorFGFR3
- Interventions
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Fusion Pharmaceuticals Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT05363605
- Locations
- 🇦🇺
St Vincent's Hospital, Melbourne, Australia
🇺🇸City of Hope, Duarte, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath